Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850036 | 0.92 | SIGMAR1 (0.58) | MAPK11MAPK14SIGMAR1 | |
| SCHEMBL5850534 | 0.92 | MAPK11 (0.56) | MAPK11MAPK14SIGMAR1MAPK1HTR1F | |
| SCHEMBL5850315 | 0.86 | SIGMAR1 (0.58) | MAPK11MAPK14SIGMAR1 | |
| SCHEMBL5849881 | 0.86 | MAPK14 (0.59) | MAPK11MAPK14SIGMAR1 | |
| SCHEMBL5851954 | 0.84 | DRD2 (0.53) | MAPK11MAPK14SIGMAR1MAPK1 | |
| SCHEMBL5648353 | 0.83 | SIGMAR1 (0.52) | MAPK11MAPK14SIGMAR1MAPK1 | |
| SCHEMBL5647452 | 0.83 | SIGMAR1 (0.52) | MAPK11MAPK14SIGMAR1MAPK1 | |
| SCHEMBL5647910 | 0.82 | HTR1A (0.49) | MAPK11MAPK14SIGMAR1 | |
| SCHEMBL5646625 | 0.82 | HTR1A (0.47) | MAPK11MAPK14SIGMAR1HTR1F | |
| Hydrochloric Acid SCHEMBL5652371 | 0.82 | HTR1A (0.49) | MAPK11MAPK14SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | claimed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | claimed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | claimed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MAPK11 3630/4885MAPK14 3902/4885SIGMAR1 881/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | MAPK11 3723/4885MAPK14 4157/4885SIGMAR1 882/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | MAPK11 3364/4885MAPK14 3593/4885SIGMAR1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.